Transport
Franciscan Health Indianapolis & Mooresville
Franciscan Health Indianapolis & Mooresville was paid $41.36M by Medicaid between Jan 2018 and Dec 2024, across 177 billing codes. Its largest line is 99284, emergency room visit (serious) — 25% of everything it billed.
33Billing provider infoFRANCISCAN HEALTH INDIANAPOLIS & MOORESVILLE
INDIANAPOLIS, IN 46237
INDIANAPOLIS, IN 46237
33aNPI1386749893assigned 09/13/2006
33bProvider typeAmbulance
28Total paid$41.36M
24GClaims702,043
24DCodes billed177
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulance providers in Indiana
Rank by total paid#1 of 85
Median peer was paid$457K
This provider vs. median90×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 94,693 | $2.09M | |
| 2019 | 75,481 | $4.35M | |
| 2020 | 74,454 | $4.82M | |
| 2021 | 102,381 | $6.80M | |
| 2022 | 124,620 | $7.93M | |
| 2023 | 125,735 | $8.52M | |
| 2024incomplete | 104,679 | $6.84M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 69,344 | 58,616 | $10.53M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 55,939 | 50,113 | $7.82M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.5% | 21,994 | 18,193 | $2.68M |
| 71045 | Radiologic examination, chest; single view | 6.2% | 19,035 | 16,094 | $2.57M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.6% | 36,147 | 29,702 | $2.34M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 3,246 | 2,696 | $1.31M |
| 93296 | 2.6% | 8,758 | 7,169 | $1.08M | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 32,944 | 27,752 | $1.01M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 5,957 | 5,461 | $851K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.9% | 11,086 | 9,947 | $769K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 19,182 | 15,458 | $745K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 14,805 | 5,164 | $472K |
165 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 82,961 | $449K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.0% | 6,328 | $415K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,541 | $388K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,786 | $388K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,150 | $385K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 9,063 | $380K |
| 95806 | <1% | 666 | $376K | |
| 99218 | <1% | 1,224 | $361K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,082 | $331K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,272 | $313K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,855 | $299K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,876 | $294K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 476 | $272K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 50,463 | $267K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,335 | $264K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,253 | $261K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,193 | $250K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,941 | $210K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 122 | $200K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 324 | $178K |
| 80053 | Comprehensive metabolic panel | <1% | 22,174 | $167K |
| 36415 | Collection of venous blood by venipuncture | <1% | 48,507 | $158K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,471 | $155K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,348 | $139K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 890 | $126K |
| 62323 | <1% | 130 | $125K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,678 | $124K |
| 62321 | <1% | 121 | $123K | |
| 84484 | <1% | 15,070 | $120K | |
| 99221 | <1% | 397 | $120K | |
| 97162 | <1% | 1,595 | $120K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,974 | $87K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,197 | $79K |
| 29580 | <1% | 1,521 | $74K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 782 | $66K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 835 | $63K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 625 | $62K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,539 | $60K |
| 81001 | <1% | 25,318 | $57K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,325 | $57K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,002 | $54K |
| 80076 | <1% | 8,810 | $48K | |
| 97161 | <1% | 571 | $48K | |
| 83690 | <1% | 8,548 | $34K | |
| 76604 | <1% | 322 | $33K | |
| 97163 | <1% | 405 | $31K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 62 | $29K |
| 93298 | <1% | 157 | $26K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,122 | $25K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 216 | $25K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 43 | $24K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 727 | $21K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 398 | $19K |
| 81025 | <1% | 3,385 | $18K | |
| 80061 | Lipid panel | <1% | 2,094 | $17K |
| 64493 | <1% | 15 | $17K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,545 | $16K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 48 | $16K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 385 | $16K |
| 84703 | <1% | 2,508 | $15K | |
| 97116 | <1% | 758 | $15K | |
| 97166 | <1% | 104 | $13K | |
| 83605 | <1% | 1,734 | $12K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 60 | $11K |
| 90839 | <1% | 171 | $10K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 138 | $9K |
| 80050 | General health panel | <1% | 93 | $9K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 162 | $9K |
| 83735 | <1% | 2,236 | $9K | |
| 83615 | <1% | 2,160 | $9K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 719 | $8K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,303 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 262 | $7K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 261 | $7K |
| 82728 | <1% | 1,013 | $7K | |
| 87634 | <1% | 115 | $7K | |
| 95886 | <1% | 15 | $7K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 245 | $7K |
| 84100 | <1% | 2,069 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 116 | $6K |
| 83970 | <1% | 382 | $6K | |
| 77336 | <1% | 25 | $5K | |
| 92523 | <1% | 31 | $5K | |
| 93225 | <1% | 19 | $5K | |
| 87631 | <1% | 38 | $4K | |
| 97167 | <1% | 48 | $4K | |
| 84702 | <1% | 391 | $4K | |
| 83880 | <1% | 139 | $4K | |
| 99201 | <1% | 155 | $3K | |
| 83540 | <1% | 744 | $3K | |
| 87276 | <1% | 572 | $3K | |
| 36416 | <1% | 181 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $3K |
| 84425 | <1% | 345 | $3K | |
| 87275 | <1% | 572 | $3K | |
| 74246 | <1% | 12 | $3K | |
| 87641 | <1% | 133 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 303 | $2K |
| 96376 | <1% | 133 | $2K | |
| 83525 | <1% | 210 | $2K | |
| 82607 | <1% | 349 | $2K | |
| 84466 | <1% | 216 | $2K | |
| 86140 | <1% | 498 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 104 | $2K |
| 82746 | <1% | 192 | $2K | |
| 85379 | <1% | 228 | $2K | |
| 86480 | <1% | 31 | $2K | |
| 92526 | <1% | 18 | $1K | |
| 96040 | <1% | 15 | $1K | |
| 36591 | <1% | 16 | $1K | |
| 93226 | <1% | 19 | $1K | |
| 84134 | <1% | 352 | $956.72 | |
| 94761 | <1% | 114 | $918.47 | |
| 73562 | <1% | 17 | $842.81 | |
| 82077 | <1% | 76 | $841.17 | |
| 84460 | <1% | 233 | $837.44 | |
| 80074 | <1% | 16 | $776.37 | |
| 88173 | <1% | 40 | $767.94 | |
| 85652 | <1% | 405 | $751.50 | |
| 64494 | <1% | 24 | $692.82 | |
| 85027 | <1% | 148 | $687.00 | |
| 84439 | <1% | 132 | $677.92 | |
| 86803 | <1% | 53 | $662.26 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 56 | $565.01 |
| 88304 | <1% | 16 | $527.24 | |
| 82565 | <1% | 136 | $458.21 | |
| 82040 | <1% | 142 | $447.22 | |
| 88172 | <1% | 40 | $426.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 16 | $392.50 |
| 97760 | <1% | 30 | $378.85 | |
| 73630 | <1% | 19 | $245.53 | |
| 82180 | <1% | 32 | $235.22 | |
| 84480 | <1% | 16 | $218.91 | |
| 80069 | <1% | 37 | $172.16 | |
| 82962 | <1% | 52 | $144.58 | |
| 72100 | <1% | 12 | $137.79 | |
| 84450 | <1% | 33 | $122.33 | |
| 83550 | <1% | 15 | $121.32 | |
| 84436 | <1% | 17 | $118.85 | |
| 81003 | <1% | 107 | $97.50 | |
| 82465 | <1% | 16 | $72.94 | |
| 82247 | <1% | 15 | $70.28 | |
| 82248 | <1% | 15 | $70.28 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 41 | $55.95 |
| 73130 | <1% | 15 | $51.03 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,294 | $14.41 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,794 | $9.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 319 | $7.98 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 630 | $0.34 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 1,055 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 1,741 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 503 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 280 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 281 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 81 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 48 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 210 | $0.00 |
| C1769 | Guide wire | 0% | 25 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 19 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 1,671 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 386 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 39 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 42 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 44 | $0.00 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHERRON, AMY (DIVISIONAL CFO)
| Provider | Location | Paid |
|---|---|---|
| Franciscan Health Indianapolis & Mooresville | Mooresville, IN | $12.35M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.